Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lisa, Massmanian"'
Publikováno v:
Clinical Pharmacology in Drug Development. 3:158-162
Tivozanib hydrochloride (tivozanib) is a potent, selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1, 2, and 3, with a long half-life. This Phase I study evaluated the effect of food on tivozanib pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4ace04e2d5e962483c99f9eba0d3997
https://doi.org/10.1002/cpdd.76
https://doi.org/10.1002/cpdd.76
Autor:
Monette M, Cotreau, Lisa, Massmanian, Andrew L, Strahs, William, Slichenmyer, Dennis L, Vargo
Publikováno v:
Clinical pharmacology in drug development. 3(2)
Tivozanib hydrochloride (tivozanib) is a potent, selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1, 2, and 3, with a long half-life. This Phase I study evaluated the effect of food on tivozanib pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::30def528ff5f2b5dd0df4c669bf55f0b
https://pubmed.ncbi.nlm.nih.gov/27128461
https://pubmed.ncbi.nlm.nih.gov/27128461
Autor:
Monette M. Cotreau, William Slichenmyer, Thomas H. King, Dennis L. Vargo, Lisa Massmanian, Strahs Andrew
Publikováno v:
Cancer Research. 72:752-752
Background: Tivozanib, a potent, selective, long-half-life tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, has demonstrated antitumor activity in a Phase II study in patients with renal cell carcinoma (RCC), and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74d0cb084d3cdcc5c058aba988eb6d8c
https://doi.org/10.1158/1538-7445.am2012-752
https://doi.org/10.1158/1538-7445.am2012-752